1. Which of the following best describes a difference between omicron compared to the delta strain of COVID-19?
A. The delta strain is more transmissible than omicron
B. The delta strain has more immune escape properties than omicron
C. Omicron may have less lung penetration than delta
D. Omicron likely causes more severe disease than delta
E. Unsure
2. Which of the following COVID-19 monoclonal antibody therapies retains in vitro activity against the omicron variant?
A. Bamlanivimab
B. Bamlanivimab plus etesevimab
C. Casirivimab/imdevimab
D. Sotrovimab
E. Unsure
3. Which of the following ambulatory therapies should not be used in pregnant women because of potential teratogenicity?
A. Molnupiravir
B. Sotrovimab
C. Remdesivir
D. Nirmatrelvir/ritonavir
E. Unsure
4. Which of the following COVID-19 vaccines is now authorized as a booster injection in adolescents aged 12–17 years?
A. Moderna
B. Janssen
C. Merck
D. Pfizer/BioNTech
E. Unsure
5. Which of the following selective serotonin reuptake inhibitors has demonstrated decreased hospital admissions of people with COVID-19 in some studies?
A. Fluoxetine
B. Citalopram
C. Escitalopram
D. Fluvoxamine
E. Unsure
6. Which of the following agents has demonstrated benefit in both ambulatory and hospitalized patients with confirmed COVID-19?
A. Remdesivir
B. Sotrovimab
C. Nirmatrelvir/ritonavir
D. Molnupiravir
E. Unsure
7. Which of the following monoclonal antibody products is now authorized by FDA to prevent COVID-19 acquisition in immunosuppressed patients?
A. Sotrovimab
B. Bamlanivimab plus etesevimab
C. Casirivimab/imdevimab
D. Tixagevimab and cilgavimab
E. Unsure
8. What timeframe is appropriate for an adult to receive an influenza vaccine and a booster COVID-19 vaccine assuming they qualify based on all other factors?
A. May receive both as long as 24 hours between injections
B. May receive both as long as 72 hours between injections
C. May receive both as long as 7 days between injections
D. May receive both on same day
E. Unsure
9. Which of the following agents would require a dose/frequency adjustment if the patient had an eGFR of 40 mL/min?
A. Sotrovimab
B. Nirmatrelvir/ritonavir
C. Remdesivir
D. Molnupiravir
E. Unsure
10. Nirmatrelvir/ritonavir should not be given with rivaroxaban because the risk of which of the following could potentially be increased?
A. Clinical failure of nirmatrelvir/ritonavir
B. Bleeding due to increased concentrations of rivaroxaban
C. Thrombotic event due to decreased concentrations of rivaroxaban
D. Hepatotoxicity caused by nirmatrelvir/ritonavir
E. Unsure
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Will the information presented cause you to change your practice?
A. Yes
B. No
21. Are you committed to making these changes?
A. Yes
B. No
22. As a result of this activity, did you learn something new?
A. Yes
B. No
23. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
24. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20